Experts Review Exciting Follicular Lymphoma Readouts from ASH 2024
By Ruemu Birhiray, MD, Joshua Brody, MD, Julio Chavez, MD - Last Updated: April 7, 2025In a roundtable discussion moderated by Ruemu Birhiray, MD of Hematology Oncology of Indiana, experts explore the latest advancements in follicular lymphoma treatment, with a focus on bispecific antibodies presented at the 66th American Society of Hematology Annual Meeting and Exposition. The experts analyze data on epcoritamab combinations, response rates, and safety, addressing community adoption challenges and strategies to enhance accessibility and tolerability.
Advertisement
Post Tags:FL Roundtable
Advertisement
Related Posts
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.